Medicare rolls out hep C screening, boosting Sovaldi prospects even further

Gilead's Sovaldi--Courtesy of Gilead

The most effective weapon to date against hepatitis C, Gilead's ($GILD) new drug Sovaldi, has raised the ire of drug-cost watchdogs worldwide with its $84,000 price tag. That's not stopping the largest U.S. government payer from giving the product--and its forthcoming competitors, also expected to be pricey--a major push. The Centers for Medicare & Medicaid Services (CMS) says it will start covering hep C screening for adults at high risk for the virus or for any of its beneficiaries born between 1945 and 1965. Report